Methods We reviewed the medical records of 341 patients with NSCLC receiving immunotherapy as between July 2013 and June 2018. Progression-free survival and overall survival was calculated using Kaplan-Meier curve.

Results The average age of patients was 66 years (range: 39–90 years), with a male predominance (57%). Majority of the patients were Caucasian (87%), followed by African-American (12%), and Asian (1%). Most of the patients were former smoker (72%), followed by current smoker (19%) and never smoker (7%). Adenocarcinoma and squamous cell carcinoma was diagnosed in 206 (60%) patients and 112 (33%) patients, respectively. The ECOG-PS was 0, 1, 2 and 3 in 46 (13%), 175 (51%), 86 (25%) and 34 (10%), respectively. Four different immunotherapies were used, namely atezolizumab in 10 (3%), durvalumab in 34 (10%), nivolumab in 152 (44%) and pembrolizumab in 144 (42%) patients. Average number of cycles of atezolizumab received by the patient was 6 (range 2–22 cycles), durvalumab 15 (range 1–29 cycles), nivolumab 11 (range 1–112 cycles), and pembrolizumab 12 (range 1–52 cycles). Patients were grouped in good performance status (ECOG 0–1) and poor performance status (ECOG ≥2). The median progression free survival (PFS) was 7 months (95% CI 6.3–8.2) in patients with good PS and 3 months (95% CI 1.8–4.6) in patients with poor performance status (p<0.001).

Conclusions Our data suggests that while the patients with poor PS tolerated the immunotherapy. However, poor PS was associated with significantly lower PFS and OS. Further studies are required to evaluate the effect of PS on survival in front-line immunotherapy.

Acknowledgements We thank Dr. Saqib Abbasi for helpful discussions.

References

N/A

Abstract 221 Figure 1 Progression free survival (PFS) and overall survival (OS) in patients with good performance status (ECOG PS 0–1) and poor performance status (ECOG ≥2) treated with immunotherapy in NSCLC

Conclusions Treatment of locally advanced, recurrent, and metastatic CSCC with ICI led to a dramatic change in the management and prognosis of CSCC. Our series of patients with CSCC had a higher than reported rate of response. This corresponded with high TP53 alterations, NOTCH 1/2 alterations, high/intermediate TMB, and high level of expression of PD-L1. PD-L1 rates were higher than previously published. 1, 2

Nate Bowers*, Kimberly Burcher, Jess Savas, Phillip Williford, Laura Doerfler, Hafiz Shabbir Patwa, Joshua Waltonen, Christopher Sullivan, James Brown, Mercedes Porosnicu.

Wake Forest, Winston Salem, NC, USA

Background PD-1 inhibitors were approved for locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC) in 2019. 1 The identification of tumor characteristics that predict potential responders to immune checkpoint inhibitors (ICI) is an area of ongoing research. Here we present a series of consecutive patients with locally advanced, recurrent, or metastatic CSCC treated with PD-1 inhibitors and analyze tumor and blood genomics as well as PD-L1 expression with the aim of correlating with treatment response.

Methods We analyzed cases of CSCC treated with single agent PD-1 inhibitors in the last 2 years at Wake Forest. Demographic and outcome data were collected. Tumor tissue, whenever available, was tested for PD-L1, TMB, MSI, and genetic mutations. Blood was tested for circulating tumor at the beginning of treatment and at the time of maximum response.

Results Fourteen patients with CSCC treated with PD-1 ICI were included in this study. Six had locally advanced disease, seven had recurrent locally advanced disease, and one had metastatic disease. Four patients received treatment for >12 months and all had complete response (CR). Five patients had 6–12 months of treatment and all had near CR (pending imaging studies and ctDNA to confirm). Three patients had <6 months of treatment and had partial response (PR). Two of the patients had progressive disease, although one with possible pseudoprogression based on review of post-treatment surgical pathology specimen. Treatment was well tolerated with no immune related side-effects except one case of grade I hypothyroidism. Eleven patients had sufficient tumor tissue for genomic and PD-L1 testing. Initial blood genomic testing was performed in 12 of 13 patients and in follow up in patients who achieved maximum response. Patients with CR had PD-L1 of at least 30%. The additional tested patients had PD-L1 above 10%. The most frequently mutated gene was TP53 present in tumor in all tested patients and in blood in 6 patients, followed by NOTCH1/2 detected in the tumor of 10 of 11 patients tested. TMB was intermediate/high in tested patients except in the only patient who presented clear tumor progression.

Conclusions Additional testing of PD-L1 with the addition of TMB, MSI, and genetic mutations may increase the identification of responders to PD-1 inhibitors in CSCC.
Ethics Approval The study was approved by Wake Forest University Institution’s Ethics Board, approval number IRB00056249.

REFERENCES


http://dx.doi.org/10.1136/jitc-2020-SITC2020.0222

RACIAL DIFFERENCES IN OUTCOMES FOR METASTATIC RENAL CELL CARCINOMA (mRCC) PATIENTS MANAGED ON IMMUNE-CHECKPOINT INHIBITOR (ICI) THERAPY

1T Anders Olsen*, 1Dylan Martini, 2Subir Goyal, 1Yuan Liu, 1Sean Evans, 1Benjamin Magod, 1Jacqueline Brown, 1Lauren Yantorni, 1Greta Rusler, 1Sarah Caulfield, 1Jamie Goldman, 1Bassel Nazha, 1Wayne Harris, 1Viraj Master, 1Omer Kucuk, 1Bradley Carthon, 1Mehmet Bilen. 1Emory University School of Medicine, Atlanta, GA, USA; 2Emory University, Atlanta, GA, USA; 3Winship Cancer Institute of Emory University, Atlanta, GA, USA

Background Immune checkpoint inhibitors (ICIs) have increased in prevalence for the treatment of metastatic clear-cell renal cell carcinoma (mccRCC) in recent years given their efficacy and favorable toxicity profile. However, there has been insufficient investigation in the literature of how clinical outcomes differ on the basis of race. In this paper, we investigated differences in clinical outcomes between African American (AA) and Caucasian mRCC patients treated with ICI therapy.

Methods We performed a retrospective study of 198 patients with mRCC who received ICI at the Emory Winship Cancer Institute from 2015–2020. Clinical outcomes were measured by overall survival (OS), progression-free survival (PFS), and clinical benefit (CB). OS and PFS were calculated from ICI-initiation to date of death and radiographic or clinical progression, respectively. CB was defined as a best radiographic response of complete response, partial response, or stable disease maintained for at least 6 months per response evaluation criteria in solid tumors version 1.1. The association of self-identified race with OS and PFS was generally modeled by Cox proportional hazards model. Univariable and multivariable logistic regression models were used for binary outcomes of CB. The univariate association of immune-related adverse events (irAEs) and non-clear-cell RCC (ncRCC) with race was assessed using Chi-square test.

Results Our cohort was made up of 38 AA (19%) and 160 Caucasian (81%) patients. Most of the patients were diagnosed with ccRCC (78%) and more than half received PD-1 monotherapy (57%). Most patients were international mRCC database consortium (IMDC) intermediate (57%) or poor-risk (25%) groups. AA patients displayed significantly shorter PFS (HR=1.52, 95% CI: 1.01–2.3, p=0.045) and trended towards decreased CB (OR=0.51, 95% CI: 0.22–1.17, p=0.111) compared to Caucasian patients (figure 1). Additionally, AA patients more commonly had nccRCC compared to Caucasian patients (41.7% vs 17.5% nccRCC, p=0.002). AA patients also trended towards a lower incidence of irAEs compared to Caucasian patients in UVA (23.7% vs 35.8%, p=0.153).

Conclusions In this group of mRCC patients treated with ICI, African American patients had significantly shorter PFS compared to Caucasian patients. These findings suggest race could play a role in the management of late-stage mRCC. Larger, prospective studies are needed to validate these findings.

Acknowledgements Research reported in this publication was supported in part by the Breen Foundation and the Biostatistics Shared Resource of Winship Cancer Institute of Emory University and NIH/NCI under award number P30CA138292. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Trial Registration Not applicable.

Ethics Approval This retrospective study was approved by the Emory University Institutional Review Board.

Consent Not applicable.

REFERENCES

Not applicable.

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0223

OUTCOMES OF STAGE IV MELANOMA IN THE ERA OF IMMUNOTHERAPY: A NATIONAL CANCER DATABASE (NCDB) ANALYSIS

Tamara Suzman*, Wei Wei, Pauline Funchian, Brian Gastman. Cleveland Clinic Foundation, Cleveland, OH, USA

Background Immunotherapy (IO) has revolutionized the treatment landscape for metastatic melanoma and is now the mainstay of treatment since the approval of ipilimumab in 2011 and anti-PD-1 therapies (nivolumab and pembrolizumab) in 2015. The majority of data stems from trials that have...